Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Stoke Therapeutics, Inc. (STOK) reported a Q4 loss of $0.18 per share, which was better than the Zacks Consensus Estimate of a $0.51 loss. This is an improvement from the $0.60 loss per share reported a year ago.
March 18, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stoke Therapeutics reported a Q4 loss of $0.18 per share, beating the expected loss of $0.51. This is an improvement from last year's $0.60 loss per share.
The better-than-expected earnings report is likely to have a positive short-term impact on STOK's stock price. Beating estimates and showing improvement from the previous year can boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100